18889881171
Kalkine 0
countryflagUS

BioCryst Pharmaceuticals Inc

Healthcare US BCRX

10.435USD
0.04(0.43%)

Last update at 2025-05-23T17:01:00Z

Day Range

10.1610.45
LowHigh

52 Week Range

4.038.88
LowHigh

Fundamentals

  • Previous Close 10.39
  • Market Cap1601.14M
  • Volume1166682
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-31.94100M
  • Revenue TTM412.58M
  • Revenue Per Share TTM2.01
  • Gross Profit TTM 10.94M
  • Diluted EPS TTM-0.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -244.38400M -181.80900M -182.81400M -108.89700M -101.25200M
Minority interest - - - - -
Net income -247.11700M -184.06200M -196.56700M -120.06500M -101.25200M
Selling general administrative 159.37M 118.82M 67.93M 37.12M 29.51M
Selling and marketing expenses - - - - -
Gross profit 264.23M 149.91M 16.14M 44.73M 20.18M
Reconciled depreciation 1.44M 0.78M 0.75M 0.72M 0.77M
Ebit -148.43500M -177.72000M -174.75700M -99.45500M -92.73800M
Ebitda -143.30800M -177.65800M -165.33700M -97.52200M -91.96800M
Depreciation and amortization 5.13M 0.06M 9.42M 1.93M 0.77M
Non operating income net other - 55.14M -2.97600M 2.45M 2.14M
Operating income -148.43500M -177.72000M -174.75700M -99.45500M -94.22000M
Other operating expenses 419.26M 334.89M 192.57M 148.29M 114.87M
Interest expense 99.09M 59.29M 14.50M 11.89M 9.18M
Tax provision 2.73M 2.25M - - -
Interest income 5.13M 0.06M 9.42M 1.93M 2.25M
Net interest income -93.96500M -59.23200M -5.08100M -9.95900M -6.92400M
Extraordinary items - - - - -
Non recurring - - 0.13M 0.38M 0.47M
Other items - - - - -
Income tax expense 2.73M 2.25M 13.75M 11.17M 2.14M
Total revenue 270.83M 157.17M 17.81M 48.84M 20.65M
Total operating expenses 412.67M 327.63M 190.89M 144.19M 114.40M
Cost of revenue 6.59M 7.26M 1.68M 4.10M 0.47M
Total other income expense net -95.94900M -4.08900M -8.05700M -9.44200M -0.10800M
Discontinued operations - - - - -
Net income from continuing ops -247.11700M -184.06200M -192.23400M -108.89700M -101.25200M
Net income applicable to common shares -247.11600M -184.06200M -182.81400M -108.89700M -101.25200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 516.96M 550.00M 588.15M 334.71M 175.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 19.54M 12.59M 9.99M 5.53M 4.42M
Total liab 972.49M 844.60M 695.14M 353.98M 137.03M
Total stockholder equity -455.52800M -1454.62100M -1207.50400M -1023.44200M -840.62800M
Deferred long term liab - - - - -
Other current liab 102.88M 87.56M 72.67M 55.61M 36.27M
Common stock 2.06M 1.88M 1.84M 1.77M 1.54M
Capital stock 2.06M 1.88M 1.84M 1.77M 1.54M
Retained earnings -1681.15900M -1454.62100M -1207.50400M -1023.44200M -840.62800M
Other liab - - - - -
Good will - - - - -
Other assets - 550.00M 588.15M - -
Cash 112.45M 304.77M 504.39M 272.13M 114.17M
Cash and equivalents - - - - -
Total current liabilities 149.99M 105.51M 103.72M 105.65M 92.33M
Current deferred revenue - 1.22M 1.42M 0.15M 2.12M
Net debt 736.27M 436.69M 88.85M -147.41000M -29.51900M
Short term debt 26.21M 2.37M 1.82M 31.18M 39.96M
Short long term debt - - - 30.00M 38.58M
Short long term debt total 848.71M 741.45M 593.24M 124.72M 84.65M
Other stockholder equity 1222.24M -1.90500M -2.02000M -1.77200M -1.58000M
Property plant equipment - 15.42M 15.19M 7.11M 7.35M
Total current assets 495.97M 516.50M 566.14M 323.80M 164.34M
Long term investments 0.00000M 18.08M 6.83M - 0.00000M
Net tangible assets - -294.59700M -147.04400M 109.33M 82.95M
Short term investments 278.34M 119.54M 3.21M 28.24M 22.05M
Net receivables 56.95M 50.60M 29.41M 8.65M 22.15M
Long term debt 811.26M 733.28M 585.46M 119.73M 41.29M
Inventory 28.68M 27.53M 15.79M 7.04M 1.55M
Accounts payable 20.89M 14.36M 27.81M 18.71M 13.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.34M 0.03M 0.18M 0.00300M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - 1.84M 1.77M 1.54M
Preferred stock total equity - - - - -
Retained earnings total equity - - -1207.50400M -1023.44200M -840.62800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 12.03M 6.81M 6.47M 3.80M 3.59M
Deferred long term asset charges - - - - -
Non current assets total 20.99M 33.50M 22.02M 10.91M 10.94M
Capital lease obligations 13.88M 8.17M 7.78M 124.72M 4.78M
Long term debt total - - 136.08M 119.73M 41.29M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -128.23800M 18.19M -6.34300M 78.28M 5.13M
Change to liabilities -22.46900M 40.70M 24.12M 14.80M 4.24M
Total cashflows from investing activities -128.23800M 15.80M -6.85600M 77.93M 4.77M
Net borrowings 73.07M 293.87M 67.45M 19.48M 6.33M
Total cash from financing activities 88.03M 359.67M 302.70M 99.10M 62.50M
Change to operating activities -2.58300M -2.98700M 4.63M 1.69M -1.11300M
Net income -247.11600M -184.06200M -182.81400M -108.89700M -101.25200M
Change in cash -201.49500M 233.39M 158.62M 87.45M -25.29300M
Begin period cash flow 507.73M 274.35M 115.72M 28.27M 53.57M
End period cash flow 306.24M 507.73M 274.35M 115.72M 28.27M
Total cash from operating activities -161.85000M -142.15700M -137.21600M -89.58400M -92.56500M
Issuance of capital stock 0.00000M 50.00M 93.28M 58.50M 53.40M
Depreciation 1.44M 0.78M 0.75M 0.72M 0.77M
Other cashflows from investing activities - - 0.00100M 78.28M 5.13M
Dividends paid - - - - -
Change to inventory -12.42300M -8.76700M -7.03900M 1.65M -1.64900M
Change to account receivables -21.47000M -23.80400M 18.53M -16.16100M 0.57M
Sale purchase of stock - 65.79M 110.54M 79.62M 56.25M
Other cashflows from financing activities 73.07M 309.67M 261.84M 40.60M 13.13M
Change to netincome 141.84M 33.00M 15.43M 18.07M 10.45M
Capital expenditures 1.35M 2.38M 0.51M 0.34M 0.37M
Change receivables - -20.81700M 13.90M -17.85300M 1.82M
Cash flows other operating - 48.33M -3.98900M 0.65M -7.83500M
Exchange rate changes - 0.07M - - -
Cash and cash equivalents changes - 233.39M 158.62M 87.45M -25.29300M
Change in working capital -58.94500M 8.12M 26.88M -0.87200M -3.53000M
Stock based compensation 44.70M 34.64M 14.79M 17.72M 9.40M
Other non cash items 98.07M 54.20M 2.43M 1.28M 0.89M
Free cash flow -163.20100M -144.54200M -137.73000M -89.92700M -92.93100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BCRX
BioCryst Pharmaceuticals Inc		 0.04 0.43% 10.44 - - 3.88 56.59 4.98 -12.2018
NVO
Novo Nordisk A/S		 -1.37 2.01% 66.80 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 66.23 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.97 0.22% 435.00 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -8.895 1.49% 587.96 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc

4505 Emperor Boulevard, Durham, NC, United States, 27703

Key Executives

Name Title Year Born
Mr. Jon P. Stonehouse CEO, Pres & Exec. Director 1961
Mr. Anthony J. Doyle Sr. VP & CFO 1980
Dr. William P. Sheridan MBBS Chief Devel. Officer 1955
Dr. Yarlagadda S. Babu Chief Discovery Officer 1953
Dr. Helen M. Thackray FAAP, M.D. Chief R&D Officer 1968
Mr. Michael L. Jones Exec. Director of Fin. & Principal Accounting Officer 1970
Ms. Alane P. Barnes Sr. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John D. Bluth Chief Communications Officer 1973
Ms. Stephanie Angelini Chief People Officer NA
Dr. Elliott T. Berger Sr. VP of Regulatory Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.